Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease

Standard

Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. / Faivre, Anna; Katsyuba, Elena; Verissimo, Thomas; Lindenmeyer, Maja; Rajaram, Renuga Devi; Naesens, Maarten; Heckenmeyer, Carolyn; Mottis, Adrienne; Feraille, Eric; Cippà, Pietro; Cohen, Clemens; Longchamp, Alban; Allagnat, Florent; Rutkowski, Joseph M; Legouis, David; Auwerx, Johan; de Seigneux, Sophie.

In: NEPHROL DIAL TRANSPL, Vol. 36, No. 1, 01.01.2021, p. 60-68.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Faivre, A, Katsyuba, E, Verissimo, T, Lindenmeyer, M, Rajaram, RD, Naesens, M, Heckenmeyer, C, Mottis, A, Feraille, E, Cippà, P, Cohen, C, Longchamp, A, Allagnat, F, Rutkowski, JM, Legouis, D, Auwerx, J & de Seigneux, S 2021, 'Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease', NEPHROL DIAL TRANSPL, vol. 36, no. 1, pp. 60-68. https://doi.org/10.1093/ndt/gfaa124

APA

Faivre, A., Katsyuba, E., Verissimo, T., Lindenmeyer, M., Rajaram, R. D., Naesens, M., Heckenmeyer, C., Mottis, A., Feraille, E., Cippà, P., Cohen, C., Longchamp, A., Allagnat, F., Rutkowski, J. M., Legouis, D., Auwerx, J., & de Seigneux, S. (2021). Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. NEPHROL DIAL TRANSPL, 36(1), 60-68. https://doi.org/10.1093/ndt/gfaa124

Vancouver

Bibtex

@article{88fce9d615164be5bfc165f65728ed5b,
title = "Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease",
abstract = "BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI).METHODS: We studied the expression of key NAD+ biosynthesis enzymes in kidney biopsies from human allograft patients and patients with chronic kidney disease (CKD) at different stages. We used ischaemia-reperfusion injury (IRI) and cisplatin injection to model AKI, urinary tract obstruction [unilateral ureteral obstruction (UUO)] and tubulointerstitial fibrosis induced by proteinuria to investigate CKD in mice. We assessed the effect of nicotinamide riboside (NR) supplementation on AKI and CKD in animal models.RESULTS: RNA sequencing analysis of human kidney allograft biopsies during the reperfusion phase showed that the NAD+ de novo synthesis is impaired in the immediate post-transplantation period, whereas the salvage pathway is stimulated. This decrease in de novo NAD+ synthesis was confirmed in two mouse models of IRI where NR supplementation prevented plasma urea and creatinine elevation and tubular injury. In human biopsies from CKD patients, the NAD+ de novo synthesis pathway was impaired according to CKD stage, with better preservation of the salvage pathway. Similar alterations in gene expression were observed in mice with UUO or chronic proteinuric glomerular disease. NR supplementation did not prevent CKD progression, in contrast to its efficacy in AKI.CONCLUSION: Impairment of NAD+ synthesis is a hallmark of AKI and CKD. NR supplementation is beneficial in ischaemic AKI but not in CKD models.",
author = "Anna Faivre and Elena Katsyuba and Thomas Verissimo and Maja Lindenmeyer and Rajaram, {Renuga Devi} and Maarten Naesens and Carolyn Heckenmeyer and Adrienne Mottis and Eric Feraille and Pietro Cipp{\`a} and Clemens Cohen and Alban Longchamp and Florent Allagnat and Rutkowski, {Joseph M} and David Legouis and Johan Auwerx and {de Seigneux}, Sophie",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.",
year = "2021",
month = jan,
day = "1",
doi = "10.1093/ndt/gfaa124",
language = "English",
volume = "36",
pages = "60--68",
journal = "NEPHROL DIAL TRANSPL",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease

AU - Faivre, Anna

AU - Katsyuba, Elena

AU - Verissimo, Thomas

AU - Lindenmeyer, Maja

AU - Rajaram, Renuga Devi

AU - Naesens, Maarten

AU - Heckenmeyer, Carolyn

AU - Mottis, Adrienne

AU - Feraille, Eric

AU - Cippà, Pietro

AU - Cohen, Clemens

AU - Longchamp, Alban

AU - Allagnat, Florent

AU - Rutkowski, Joseph M

AU - Legouis, David

AU - Auwerx, Johan

AU - de Seigneux, Sophie

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI).METHODS: We studied the expression of key NAD+ biosynthesis enzymes in kidney biopsies from human allograft patients and patients with chronic kidney disease (CKD) at different stages. We used ischaemia-reperfusion injury (IRI) and cisplatin injection to model AKI, urinary tract obstruction [unilateral ureteral obstruction (UUO)] and tubulointerstitial fibrosis induced by proteinuria to investigate CKD in mice. We assessed the effect of nicotinamide riboside (NR) supplementation on AKI and CKD in animal models.RESULTS: RNA sequencing analysis of human kidney allograft biopsies during the reperfusion phase showed that the NAD+ de novo synthesis is impaired in the immediate post-transplantation period, whereas the salvage pathway is stimulated. This decrease in de novo NAD+ synthesis was confirmed in two mouse models of IRI where NR supplementation prevented plasma urea and creatinine elevation and tubular injury. In human biopsies from CKD patients, the NAD+ de novo synthesis pathway was impaired according to CKD stage, with better preservation of the salvage pathway. Similar alterations in gene expression were observed in mice with UUO or chronic proteinuric glomerular disease. NR supplementation did not prevent CKD progression, in contrast to its efficacy in AKI.CONCLUSION: Impairment of NAD+ synthesis is a hallmark of AKI and CKD. NR supplementation is beneficial in ischaemic AKI but not in CKD models.

AB - BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI).METHODS: We studied the expression of key NAD+ biosynthesis enzymes in kidney biopsies from human allograft patients and patients with chronic kidney disease (CKD) at different stages. We used ischaemia-reperfusion injury (IRI) and cisplatin injection to model AKI, urinary tract obstruction [unilateral ureteral obstruction (UUO)] and tubulointerstitial fibrosis induced by proteinuria to investigate CKD in mice. We assessed the effect of nicotinamide riboside (NR) supplementation on AKI and CKD in animal models.RESULTS: RNA sequencing analysis of human kidney allograft biopsies during the reperfusion phase showed that the NAD+ de novo synthesis is impaired in the immediate post-transplantation period, whereas the salvage pathway is stimulated. This decrease in de novo NAD+ synthesis was confirmed in two mouse models of IRI where NR supplementation prevented plasma urea and creatinine elevation and tubular injury. In human biopsies from CKD patients, the NAD+ de novo synthesis pathway was impaired according to CKD stage, with better preservation of the salvage pathway. Similar alterations in gene expression were observed in mice with UUO or chronic proteinuric glomerular disease. NR supplementation did not prevent CKD progression, in contrast to its efficacy in AKI.CONCLUSION: Impairment of NAD+ synthesis is a hallmark of AKI and CKD. NR supplementation is beneficial in ischaemic AKI but not in CKD models.

U2 - 10.1093/ndt/gfaa124

DO - 10.1093/ndt/gfaa124

M3 - SCORING: Journal article

C2 - 33099633

VL - 36

SP - 60

EP - 68

JO - NEPHROL DIAL TRANSPL

JF - NEPHROL DIAL TRANSPL

SN - 0931-0509

IS - 1

ER -